Incyte to Present New Data on Dermatology Portfolio at EADV Congress 2023
Incyte, a global biopharmaceutical company, has announced that multiple abstracts featuring new data from its dermatology portfolio have been accepted for presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2023. The congress will take place in Berlin from October 11-14.
The abstracts will cover various topics related to dermatology, including vitiligo, atopic dermatitis (AD), and hidradenitis suppurativa. Notably, Incyte will present late-breaking data on the use of ruxolitinib cream for patients with vitiligo and AD. One presentation will focus on the prolonged use of ruxolitinib cream for vitiligo patients who initially had limited or no response, while another will present the full results of the TRuE-AD3 trial in pediatric AD.
Dr. Jim Lee, Group Vice President of Inflammation & Autoimmunity at Incyte, expressed his satisfaction with the data being presented at the congress. He emphasized the company’s commitment to advancing treatment options for the dermatology community.
In addition to the late-breaking presentations, Incyte-sponsored programs will also feature oral presentations and ePosters on topics such as hidradenitis suppurativa, vitiligo treatment patterns, and the impact of ruxolitinib cream on itch reduction in adults with AD.
Opzelura® (ruxolitinib) Cream 1.5%, a topical treatment for nonsegmental vitiligo and mild to moderate AD, will be a key focus of the presentations. Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.
The EADV Congress 2023 program provides full details of the sessions and data presentations.
Incyte’s dermatology research and development efforts are centered around leveraging its expertise in the JAK-STAT pathway. The company is dedicated to discovering and developing innovative treatments for immune-mediated dermatologic conditions with high unmet medical needs.
For more information on Incyte’s dermatology portfolio, visit the Dermatology section of their website.
About Incyte:
Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware. The company focuses on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics.
Source: [Insert source link here]